Search Results 281-290 of 17407 for Interferon

  1. Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases - Mayo Clinic

    Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon, kinase inhibitors or other targeted small molecules, and toxin ...

  2. https://www.mayoclinic.org/spanish_organization_concepts.xml

  3. Immune Response to Antigens - Clinical Trials

    The purpose of this study is to sequence patient germline and tumor samples, and nominate top neoantigen candidates using an in-house developed bioinformatics ...

  4. Discovery's Edge: Cleaning up cancer - Mayo Clinic News Network

    Chen's laboratory discovered that when the immune system produced the cancer-fighting protein interferon gamma, the tumor cells produced the B7-H1 molecule to ...

  5. A Study Comparing 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR to Treat Patients with Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours - Mayo Clinic

    Interferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks prior to randomization in the study. Known brain metastases, unless ...

  6. Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET - Mayo Clinic

    * Any previous therapy with interferons, mTOR-inhibitors, chemotherapy or other systemic therapies except somatostatin analogues (SSAs) of GEP-NET. If as ...

  7. Publications - Katie T. Anderson, M.D. - Mayo Clinic

    The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer. Adv Urol. 2015; 2015:656918 Epub 2015 Oct 13. View PubMed ...

  8. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

    interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to randomization - Treatment with systemic immunosuppressive medications (including, but ...

  9. A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy - Mayo Clinic

    Treatment with systemic immunostimulatory agents (including, but not limited to, interferons or interleukin-2) within 6 weeks or five half-lives of the drug, ...

  10. https://www.mayoclinic.org/arabic_organization_concepts.xml